Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model
Authors
Keywords
-
Journal
NUCLEIC ACIDS RESEARCH
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-02-20
DOI
10.1093/nar/gkaa126
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treating Disease at the RNA Level with Oligonucleotides
- (2019) Arthur A. Levin NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Antisense Oligonucleotides Are Coming of Age
- (2019) C. Frank Bennett Annual Review of Medicine
- Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly
- (2019) Ying Wang et al. Nucleic Acid Therapeutics
- Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy
- (2018) Gillian K. Maxwell et al. JOURNAL OF ANATOMY
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the effect of 2′-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice
- (2018) Thazha P. Prakash et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Downregulation of Survivin contributes to cell-cycle arrest during postnatal cardiac development in a severe spinal muscular atrophy mouse model
- (2017) Lei Sheng et al. HUMAN MOLECULAR GENETICS
- A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy
- (2017) Xingxing Wu et al. HUMAN MOLECULAR GENETICS
- FDA-Approved Oligonucleotide Therapies in 2017
- (2017) Cy A. Stein et al. MOLECULAR THERAPY
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides
- (2017) Annemieke Aartsma-Rus Nucleic Acid Therapeutics
- Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment
- (2017) Valérie Robin et al. Molecular Therapy-Nucleic Acids
- Eteplirsen: First Global Approval
- (2016) Yahiya Y. Syed DRUGS
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
- (2016) Richard S Finkel et al. LANCET
- Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
- (2016) Suzan M. Hammond et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antisense rescues babies from killer disease
- (2016) Meredith Wadman SCIENCE
- Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides
- (2016) Te-Lin Lin et al. PLoS One
- Survival Motor Neuron (SMN) protein is required for normal mouse liver development
- (2016) Eva Szunyogova et al. Scientific Reports
- Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models
- (2015) Yimin Hua et al. GENES & DEVELOPMENT
- Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response
- (2015) Haiyan Zhou et al. HUMAN MOLECULAR GENETICS
- Phosphorothioate oligonucleotides can displaceNEAT1RNA and form nuclear paraspeckle-like structures
- (2014) Wen Shen et al. NUCLEIC ACIDS RESEARCH
- Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing
- (2012) Frank Rigo et al. Nature Chemical Biology
- Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases
- (2012) Amber L. Southwell et al. TRENDS IN MOLECULAR MEDICINE
- A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse
- (2011) Paul N. Porensky et al. HUMAN MOLECULAR GENETICS
- Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy
- (2011) K. K. Y. Ling et al. HUMAN MOLECULAR GENETICS
- Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
- (2011) Yimin Hua et al. NATURE
- Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
- (2011) M. A. Passini et al. Science Translational Medicine
- Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
- (2010) Y. Hua et al. GENES & DEVELOPMENT
- Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN
- (2010) Kevin D Foust et al. NATURE BIOTECHNOLOGY
- Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy
- (2009) J. H. Williams et al. JOURNAL OF NEUROSCIENCE
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice
- (2008) Yimin Hua et al. AMERICAN JOURNAL OF HUMAN GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started